Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has shared an announcement.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the proposed adoption of a 2025 Share Incentive Scheme, pending shareholder approval at a general meeting. This scheme aims to establish a long-term incentive mechanism to attract and retain participants, aligning their interests with the company’s strategic goals and fostering its long-term development. The scheme will be valid for ten years, and the company may issue new shares or utilize treasury shares to satisfy the grant of share awards, thereby potentially impacting its market operations and stakeholder interests.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the biopharmaceutical industry. The company focuses on developing and promoting biopharmaceutical products, aiming to enhance its market position through strategic initiatives such as share incentive schemes.
Average Trading Volume: 643,308
Technical Sentiment Signal: Buy
Current Market Cap: HK$99.48B
Learn more about 6990 stock on TipRanks’ Stock Analysis page.